|
1.
|
Matthews JI and Blanton HM: Lung cancer.
An update. Prim Care. 12:267–281. 1985.
|
|
2.
|
Landi MT, Consonni D, Rotunno M, Bergen
AW, Goldstein AM, Lubin JH, Goldin L, Alavanja M, Morgan G, Subar
AF, Linnoila I, Previdi F, Corno M, Rubagotti M, Marinelli B,
Albetti B, Colombi A, Tucker M, Wacholder S, Pesatori AC, Caporaso
NE and Bertazzi PA: Environment and genetics in lung cancer
etiology (EAGLE) study: an integrative population-based
case-control study of lung cancer. BMC Public Health. 8:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133.
2011.PubMed/NCBI
|
|
5.
|
Petty RD, Nicolson MC, Kerr KM,
Collie-Duguid E and Murray GI: Gene expression profiling in
non-small cell lung cancer: from molecular mechanisms to clinical
application. Clin Cancer Res. 10:3237–3248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Normanno N, Campiglio M, De LA, Somenzi G,
Maiello M, Ciardiello F, Gianni L, Salomon DS and Menard S:
Cooperative inhibitory effect of ZD1839 (Iressa) in combination
with trastuzumab (Herceptin) on human breast cancer cell growth.
Ann Oncol. 13:65–72. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Doody JF, Wang Y, Patel SN, Joynes C, Lee
SP, Gerlak J, Rolser RL, Li Y, Steiner P, Bassi R, Hicklin DJ and
Hadari YR: Inhibitory activity of cetuximab on epidermal growth
factor receptor mutations in non small cell lung cancers. Mol
Cancer Ther. 6:2642–2651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Camidge DR: The potential of death
receptor 4- and 5-directed therapies in the treatment of lung
cancer. Clin Lung Cancer. 8:413–419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bivona TG, Hieronymus H, Parker J, Chang
K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C,
Hannon G and Sawyers CL: FAS and NF-κB signalling modulate
dependence of lung cancers on mutant EGFR. Nature. 471:523–526.
2011.
|
|
11.
|
Mukohara T, Engelman JA, Hanna NH, Yeap
BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z,
Cantley LC, Tenen DG, Johnson BE and Jänne PA: Differential effects
of gefitinib and cetuximab on non-small-cell lung cancers bearing
epidermal growth factor receptor mutations. J Natl Cancer Inst.
97:1185–1194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lieber M, Smith B, Szakal A, Nelson-Rees W
and Todaro G: A continuous tumor-cell line from a human lung
carcinoma with properties of type II alveolar epithelial cells. Int
J Cancer. 17:62–70. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Amann J, Kalyankrishna S, Massion PP, Ohm
JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart
Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD,
Kurie JM and Carbone DP: Aberrant epidermal growth factor receptor
signaling and enhanced sensitivity to EGFR inhibitors in lung
cancer. Cancer Res. 65:226–235. 2005.PubMed/NCBI
|
|
14.
|
Hur DY, Kim S, Kim YI, Min HY, Kim DJ, Lee
DS, Cho D, Hwang YI, Hwang DH, Park SH, Ahn HK, Chang KY, Kim YB
and Lee WJ: CM1, a possible novel activation molecule on human
lymphocytes. Immunol Lett. 74:95–102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kim D, Hur DY, Kim YS, Lee K, Lee Y, Cho
D, Kang JS, Kim YI, Hahm E, Yang Y, Yoon S, Kim S, Lee WB, Park HY,
Kim YB, Hwang YI, Chang KY and Lee WJ: CM1 ligation initiates
apoptosis in a caspase 8-dependent manner in Ramos cells and in a
mitochondria-controlled manner in Raji cells. Hum Immunol.
63:576–587. 2002. View Article : Google Scholar
|
|
16.
|
Kim YS, Park GB, Choi YM, Kwon OS, Song
HK, Kang JS, Kim YI, Lee WJ and Hur DY: Ligation of
centrocyte/centroblast marker 1 on Epstein-Barr virus-transformed B
lymphocytes induces cell death in a reactive oxygen
species-dependent manner. Hum Immunol. 67:795–807. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Gamaley IA and Klyubin IV: Roles of
reactive oxygen species: signaling and regulation of cellular
functions. Int Rev Cytol. 188:203–255. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Moldovan L and Moldovan NI: Oxygen free
radicals and redox biology of organelles. Histochem Cell Biol.
122:395–412. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ushio-Fukai M and Alexander RW: Reactive
oxygen species as mediators of angiogenesis signaling: role of
NAD(P)H oxidase. Mol Cell Biochem. 264:85–97. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Andreyev AY, Kushnareva YE and Starkov AA:
Mitochondrial metabolism of reactive oxygen species. Biochemistry
(Mosc). 70:200–214. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Facchinetti F, Furegato S, Terrazzino S
and Leon A: H(2) O(2) induces upregulation of Fas and Fas ligand
expression in NGF-differentiated PC12 cells: modulation by cAMP. J
Neurosci Res. 69:178–188. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chen L, Park SM, Tumanov AV, Hau A, Sawada
K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E and Peter ME:
CD95 promotes tumour growth. Nature. 465:492–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Jia L, Macey MG, Yin Y, Newland AC and
Kelsey SM: Subcellular distribution and redistribution of Bcl-2
family proteins in human leukemia cells undergoing apoptosis.
Blood. 93:2353–2359. 1999.PubMed/NCBI
|
|
24.
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vander Heiden MG, Chandel NS, Williamson
EK, Schumacker PT and Thompson CB: Bcl-xL regulates the membrane
potential and volume homeostasis of mitochondria. Cell. 91:627–637.
1997.PubMed/NCBI
|
|
26.
|
Rossé T, Olivier R, Monney L, Rager M,
Conus S, Fellay I, Jansen B and Borner C: Bcl-2 prolongs cell
survival after Bax-induced release of cytochrome c. Nature.
391:496–499. 1998.PubMed/NCBI
|
|
27.
|
Yang E, Zha J, Jockel J, Boise LH,
Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for
Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell.
80:285–291. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yu C, Rahmani M, Almenara J, Sausville EA,
Dent P and Grant S: Induction of apoptosis in human leukemia cells
by the tyrosine kinase inhibitor adaphostin proceeds through a
RAF-1/MEK/ERK- and AKT-dependent process. Oncogene. 23:1364–1376.
2004. View Article : Google Scholar
|
|
30.
|
Van Laethem A, Van Kelst S, Lippens S,
Declercq W, Vandenabeele P, Janssens S, Vandenheede JR, Garmyn M
and Agostinis P: Activation of p38 MAPK is required for Bax
translocation to mitochondria, cytochrome c release and apoptosis
induced by UVB irradiation in human keratinocytes. FASEB J.
18:1946–1948. 2004.PubMed/NCBI
|
|
31.
|
Liu WH and Chang LS: Piceatannol induces
Fas and FasL up-regulation in human leukemia U937 cells via
Ca2+/p38alpha MAPK-mediated activation of c-Jun and
ATF-2 pathways. Int J Biochem Cell Biol. 42:1498–1506. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Duan SG, Cheng L, Li DJ, Zhu J, Xiong Y,
Li XW and Wang SG: The role of MAPK-ERK pathway in 67-kDa laminin
receptor-induced FasL expression in human cholangiocarcinoma cells.
Dig Dis Sci. 55:2844–2852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Takeuchi K, Shin-ya T, Nishio K and Ito F:
Mitogen-activated protein kinase phosphatase-1 modulated JNK
activation is critical for apoptosis induced by inhibitor of
epidermal growth factor receptor-tyrosine kinase. FEBS J.
276:1255–1265. 2009. View Article : Google Scholar
|
|
34.
|
Bröker LE, Kruyt FA and Giaccone G: Cell
death independent of caspases: a review. Clin Cancer Res.
11:3155–3162. 2005.
|
